Comparative Evaluation of Gabapentine and Occlusal Splint in the Management of Sleep Bruxism

This study has been completed.
Sponsor:
Information provided by:
Mashhad University of Medical Sciences
ClinicalTrials.gov Identifier:
NCT01255878
First received: December 7, 2010
Last updated: NA
Last verified: December 2010
History: No changes posted
  Purpose

Sleep bruxism (SB) is defined as a "stereotyped movement disorder characterized by grinding or clenching of the teeth during sleep" usually associated with sleep arousal. It might lead to abrasive tooth wear, hypermobility of teeth, tooth hypersensitivity, hypertrophy of the masticatory muscles and pain in the masticatory muscles.

Diagnostic procedures include clinical evaluation, ambulatory monitoring sleep laboratory investigations and others. The clinical approach comprises the patient's history, orofacial examination, and tooth wear classification.

There is no specific treatment for bruxism. Management of SB comprises psychological, orodental and pharmacological strategies.Orodental therapies, including soft vinyl mouth guards or stabilization bite splints, probably function more like protectors of the orofacial structures rather than actually diminishing bruxism.Drug treatment of sleep bruxism is controversial since different treatment strategies have resulted in suppression or exacerbation of this condition.

Based on the current data, central primary efferents are the major drivers of bruxism. Therefore centrally acting agents such as antiepileptic drugs which also affect the sleep structure, might be effective on SB.

In a case report of bruxism, anxiety and tremor, the authors suggested that anti-convulsant Gabapentine may be a useful treatment for patients with antidepressant-induced bruxism. However in the absence of definitive evidence, the appropiate treatment of SB is still a matter of debate.

The objective of the present study was to compare the treatment efficacy of occlusal stabilization splint and Gabapentine on SB, using polysomnographically determined outcome measures for the quantification of sleep bruxism.


Condition Intervention
Sleep Bruxism
Device: occlusal stabilization splint
Drug: Gabapentine

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Efficacy of Gabapentine and Splint Therapy in Bruxers: a Randomized Clinical Trial

Resource links provided by NLM:


Further study details as provided by Mashhad University of Medical Sciences:

Enrollment: 20
Study Start Date: March 2010
Study Completion Date: November 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: stabilization splint Device: occlusal stabilization splint
Experimental: Gabapentine Drug: Gabapentine
100 mg(1 capsule)three times per day for two months

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Clinical and polysomnographic criteria of sleep bruxism according to the international classification of sleep disorders

Exclusion Criteria:

  • Loss of more than two teeth and having removable prosthesis
  • Presence of a major malocclusion
  • Using any medication with a known influence on sleep structure or sleep bruxism
  • Being diagnosed with psychological or neurotic disorders.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01255878

Locations
Iran, Islamic Republic of
Mashhad University Of Medical Sciences
Mashhad, Khorasan Razavi, Iran, Islamic Republic of, 91735
Sponsors and Collaborators
Mashhad University of Medical Sciences
Investigators
Study Director: Azamsadat Madani, Dr Mashhad University of Medical Sciences
Principal Investigator: Nadia Hasanzadeh, Dr Mashhad University of Medical Sciences
Principal Investigator: Hasan Azangoo, Dr Mashhad University of Medical Sciences
Study Director: Ebrahim Abdollahian, Dr Mashhad University of Medical Sciences
  More Information

Publications:

Responsible Party: Mashhad University of Medical Sciences
ClinicalTrials.gov Identifier: NCT01255878     History of Changes
Other Study ID Numbers: 87284
Study First Received: December 7, 2010
Last Updated: December 7, 2010
Health Authority: Iran: Ethics Committee

Keywords provided by Mashhad University of Medical Sciences:
Sleep bruxism
Gabapentine
Occlusal splint
Polysomnography

Additional relevant MeSH terms:
Bruxism
Sleep Bruxism
Mental Disorders
Nervous System Diseases
Parasomnias
Sleep Disorders
Stomatognathic Diseases
Tooth Diseases
Salicylic Acid
Anti-Infective Agents
Antifungal Agents
Dermatologic Agents
Keratolytic Agents
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on October 21, 2014